Good MorningU.S. stock markets were relatively calm again on Tuesday as traders gear up for the Q1 earnings onslaught. The S&P 500 was able to edge higher but by less than half a percent to set a new all-time high. The market is being led higher by the analyst’s sentiment and a rising consensus for Q1 results. The risk for the market is that with the S&P 500 so highly valued there is a risk Q1 earnings could turn into a sell-the-news event.
Trading could take on a different tone after today. Between expected earnings reports from the big banks and economic data in the form of the Fed’s Beige Book, there is a lot of risk for the market. Among those reporting are J.P. Morgan, Goldman Sachs, and Wells Fargo. As for the Beige Book, the market will be watching it closely for any signs of rising inflation and there are sure to be some.
Featured: The case for trading fewer setups, not more (Ad) 
|
Technology | | NXP Semiconductors (NASDAQ: NXPI) had a rough 2020. The company – which derives nearly half of its revenue from its automotive business – saw full-year revenue drop 3% yoy to $8.6 billion.
But that 3% dip doesn’t tell the whole story – it was an uneven year for NXP. In the s... Read the Full Story |
|
From Our Partners | | Oracle runs 15,000 stocks through the same filter every single day, scanning for precise setups before the opening bell - no emotion, no guesswork.
Tim Bohen, Lead Trainer at StocksToTrade, is walking through this week's flagged setups and showing exactly how the scanner works in a live training right now. | | Watch the scanner in action and join the live training now |
|
Basic Materials | | It’s safe to say that one of the biggest concerns that economists and investors have on their minds at this time is inflation. With historic amounts of fiscal stimulus being added to the economy and steadily increasing government spending, many believe that widespread inflation is already occu... Read the Full Story |
|
Technology | | Back in March 2020, when lockdowns began and businesses were shut down, investors lost confidence in everything, even online payment systems such as PayPal (NASDAQ: PYPL), Square (NYSE: SQ) and Shift4 (NYSE: FOUR).
Analysts and investors initially expected economic devastation, not anticipating th... Read the Full Story |
|
From Our Partners | | Washington has taken an ownership stake in Intel, carved out a cut of Nvidia's and AMD's chip sales, and reportedly fielded an offer to own 5% of the largest AI company on the planet. The government is shifting from referee to shareholder in the most important technology race of the century.
When the rules change, the winning trades change with them. Some blue chips sitting in your index fund are now on the wrong side of this shift - while a select group of companies pulled into the new arrangement may be treated like national treasures. | | Watch the documentary to see which stocks to buy and sell now |
|
Markets | |
In the world of professional sports, defense often wins championships. In stock investing, defensive companies typically don't produce championship caliber returns. This role is usually best left for cyclical, high-growth stocks.
Sometimes, however, the tables are turned, and the defense goes on ... Read the Full Story |
|
Markets | | Media company Discovery Networks (NASDAQ: DISCA) stock experienced a questionable price surge on the coattails of peer Viacom (NYSE: VIAC). Subsequently, Discovery Networks shares also shadowed Viacom’s implosion and volatility as news of Archegos Capital Management margin calls triggered forc... Read the Full Story |
|
From Our Partners | | The U.S. government has taken roughly a 10% stake in Intel, negotiated a 15% cut of Nvidia and AMD chip sales to China, and reportedly received a 5% ownership offer - worth around $40 billion - from the most valuable AI company on earth.
Porter Stansberry calls it the New U.S.A.I. - a state-backed arrangement where Washington and a handful of tech giants are fused at the balance sheet. A small number of companies get pulled inside. Everyone else gets frozen out, including names sitting in your index fund right now. | | Watch the documentary to see which companies are on the right side |
|
Finance | |
When a company has a high-profit margin, this can be a sign of a strong business model, pricing power, a competitive advantage, or all of the above. It can also translate into excellent earnings growth and above-market returns for shareholders.
While big gains can result from rolling the dice on ... Read the Full Story |
|
Retail/Wholesale | | Lovesac Is A Couch Every Parent Should Own
We began to fall in love with the Lovesac (NASDAQ: LOVE) hyper-growth story last year. The company’s robust double-digit growth was unfazed by the pandemic and was in fact accelerating in the second half of the year. Since then we’ve learned m... Read the Full Story |
|
Markets | |
During the Reddit-fueled short squeeze days of late-January Bed Bath & Beyond (NASDAQ:BBBY) was among the companies targeted by retail traders. In a matter of a few days the highly shorted stock doubled making it one of the most notorious meme stocks.
Three months later, the stock has returne... Read the Full Story |
|
Transportation | |
Spirit Airlines (NYSE: SAVE) and JetBlue (NASDAQ: JBLU) are the latest two airlines to grab the attention of Wall Street as the economic recovery continues to gather pace. Last week we covered similar moves with United (NASDAQ: UAL) and Alaska (NYSE: ALK) so it’s clear the upside potential i... Read the Full Story |
|
Technology | | It’s safe to say that NVIDIA (NASDAQ:NVDA) just had a very successful investor day given the price action of the stock following the event. Investor days can be hit or miss for companies depending on what their respective management teams have planned and the market’s overall reception o... Read the Full Story |
|
The Early Bird Stock Of The Day Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. | | View Today's Stock Pick |
|
